Vertex Pharmaceuticals Incorporated (ETR:VX1)
352.35
-8.65 (-2.40%)
Nov 7, 2025, 5:35 PM CET
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $3.08B USD in the quarter ending September 30, 2025, with 10.99% growth. This brings the company's revenue in the last twelve months to $11.72B, up 10.33% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.72B
Revenue Growth
+10.33%
P/S Ratio
9.16
Revenue / Employee
$1.92M
Employees
6,100
Market Cap
91.54B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 46.17B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.22B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.40B |
Vertex Pharmaceuticals News
- 1 day ago - Agree To Buy Vertex Pharmaceuticals At $290, Earn 6.5% Using Options - Nasdaq
- 1 day ago - Artisan Global Opportunities Fund Q3 2025 Portfolio Update - Seeking Alpha
- 2 days ago - VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve? - Nasdaq
- 2 days ago - Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy" - Seeking Alpha
- 3 days ago - Committee stocks on the move: Uber and Vertex Pharma - CNBC
- 3 days ago - RBC Capital Maintains Vertex Pharmaceuticals (VRTX) Rating, Lowers Price Target | VRTX Stock News - GuruFocus
- 3 days ago - Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint - Nasdaq
- 3 days ago - VRTX: Stifel Lowers Price Target While Maintaining Hold Rating | VRTX Stock News - GuruFocus